CN Patent

CN119306715A — 苯基取代的二氢萘啶类化合物的晶体及其用途

Assigned to Jiangsu Suzhong Pharmaceutical Research Institute Co ltd · Expires 2025-01-14 · 1y expired

What this patent protects

本发明公开了苯基取代的二氢萘啶类化合物的晶体及其用途，属于医药技术领域。本发明公开的化合物的晶体为化合物36或化合物62，其可用作盐皮质激素受体拮抗剂，用于治疗、预防或减轻患者醛甾酮过多症、糖尿病肾病、高血压、心力衰竭(包括慢性心力衰竭等)、心肌梗死的后遗症、肝硬化、肾衰竭和中风等疾病。

USPTO Abstract

本发明公开了苯基取代的二氢萘啶类化合物的晶体及其用途，属于医药技术领域。本发明公开的化合物的晶体为化合物36或化合物62，其可用作盐皮质激素受体拮抗剂，用于治疗、预防或减轻患者醛甾酮过多症、糖尿病肾病、高血压、心力衰竭(包括慢性心力衰竭等)、心肌梗死的后遗症、肝硬化、肾衰竭和中风等疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN119306715A
Jurisdiction
CN
Classification
—
Expires
2025-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Suzhong Pharmaceutical Research Institute Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.